Investor Presentaiton

CDMO - Synthesis Demand acceleration intact; Focus on scientific led approach to BD YOY 9% 47% 32% 34% 37% 35% 62% 19% 95% 34% 63% 105% 272% 248% 78% [Cr] 720 642 577 Consistent Revenue growth every quarter in Baseline projects except for large purchase order (PO) supplies for a Big Pharma 360 176 195 207 148 155 73 86 78 100 116 127 250 228 224 PO supplies T 1Q FY20 2Q FY20 3Q 4Q 1Q FY20 FY20 FY21 FY21 2Q 3Q FY21 4Q 1Q 2Q 3Q FY21 FY22 FY22 FY22 Λ 4Q FY22 1Q 2Q 3Q 4Q 1Q 2Q FY23 FY23 FY23 FY23 FY24 FY24 Comments Y-o-Y 69% Q-o-Q 10% ■ Demand in Baseline projects accelerating and expect to lead the future growth. Q2 and H1 decline due to PO supplies last year Focused on leveraging integrated CDMO enabling platform to achieve diversified revenue stream ensuring resilience ■ Cumulative pipeline of 60+ active projects (Phase I, II, III + CMO). 10 projects commercial (4 API's & several intermediates) ■ ■ Expanding multi-year Ag-chem relationship on critical Als supply. Commercial manufacturing to begin in 2HFY25 Integrated capability expansion on track - Animal health unit started commercial validations supplies. R&D center coming on line by FY24 end ^ Completed PO related material supplies in Dec'22 22 22 Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023 LAURUS Labs Knowledge. Innovation. Excellence

View entire presentation